Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience

Autores
Guelman, Rodolfo; Sánchez, Ariel; Varsavsky, Mariela; Brun, Lucas Ricardo Martín; García, María Laura; Sarli, Marcelo; Paula, Rey; Farias, Vanina; Zanchetta, María Belén; Giacoia, Evangelina; Salerni, Helena; Maffei, Laura; Premrou, Valeria; Oliveri, Beatriz; Brance, María Lorena; Pavlove, Magdalena; Karlsbrum, Silvia; Larroudé, María Silvia; Costanzo, Pablo René
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6-12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR.
Fil: Guelman, Rodolfo. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina
Fil: Varsavsky, Mariela. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Laboratorio de Biología Ósea; Argentina
Fil: García, María Laura. Sanatorio Julio Méndez; Argentina
Fil: Sarli, Marcelo. Universidad del Salvador; Argentina
Fil: Paula, Rey. Universidad del Salvador; Argentina
Fil: Farias, Vanina. Universidad del Salvador; Argentina
Fil: Zanchetta, María Belén. Universidad del Salvador; Argentina
Fil: Giacoia, Evangelina. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Salerni, Helena. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo; Argentina
Fil: Maffei, Laura. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, Valeria. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Oliveri, Beatriz. Mautalen Salud E Investigación; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Reumatología y Enfermedades Óseas; Argentina
Fil: Pavlove, Magdalena. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Karlsbrum, Silvia. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Larroudé, María Silvia. Centro Rossi; Argentina
Fil: Costanzo, Pablo René. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Materia
Teriparatide
Bone Mineral Density
Bone Markers
Real-Life
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/218895
Acceder
id CONICETDig_648114180b88644eaa8a65bd73f52855
oai_identifier_str oai:ri.conicet.gov.ar:11336/218895
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine ExperienceGuelman, RodolfoSánchez, ArielVarsavsky, MarielaBrun, Lucas Ricardo MartínGarcía, María LauraSarli, MarceloPaula, ReyFarias, VaninaZanchetta, María BelénGiacoia, EvangelinaSalerni, HelenaMaffei, LauraPremrou, ValeriaOliveri, BeatrizBrance, María LorenaPavlove, MagdalenaKarlsbrum, SilviaLarroudé, María SilviaCostanzo, Pablo RenéTeriparatideBone Mineral DensityBone MarkersReal-Lifehttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6-12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR.Fil: Guelman, Rodolfo. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Sánchez, Ariel. Centro de Endocrinología; ArgentinaFil: Varsavsky, Mariela. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaFil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Laboratorio de Biología Ósea; ArgentinaFil: García, María Laura. Sanatorio Julio Méndez; ArgentinaFil: Sarli, Marcelo. Universidad del Salvador; ArgentinaFil: Paula, Rey. Universidad del Salvador; ArgentinaFil: Farias, Vanina. Universidad del Salvador; ArgentinaFil: Zanchetta, María Belén. Universidad del Salvador; ArgentinaFil: Giacoia, Evangelina. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Salerni, Helena. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo; ArgentinaFil: Maffei, Laura. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Premrou, Valeria. Consultorios Asociados de Endocrinología Dra. Laura Maffei; ArgentinaFil: Oliveri, Beatriz. Mautalen Salud E Investigación; ArgentinaFil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Reumatología y Enfermedades Óseas; ArgentinaFil: Pavlove, Magdalena. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Karlsbrum, Silvia. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; ArgentinaFil: Larroudé, María Silvia. Centro Rossi; ArgentinaFil: Costanzo, Pablo René. Hospital Italiano. Instituto Universitario. Escuela de Medicina; ArgentinaHindawi Publishing Corporation2023-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/218895Guelman, Rodolfo; Sánchez, Ariel; Varsavsky, Mariela; Brun, Lucas Ricardo Martín; García, María Laura; et al.; Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience; Hindawi Publishing Corporation; International Journal of Endocrinology; 2023; 9355672 ; 1-2023; 1-81687-83371687-8345CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1155/2023/9355672info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/ije/2023/9355672/info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T09:55:53Zoai:ri.conicet.gov.ar:11336/218895instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 09:55:54.027CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
title Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
spellingShingle Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
Guelman, Rodolfo
Teriparatide
Bone Mineral Density
Bone Markers
Real-Life
title_short Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
title_full Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
title_fullStr Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
title_full_unstemmed Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
title_sort Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
dc.creator.none.fl_str_mv Guelman, Rodolfo
Sánchez, Ariel
Varsavsky, Mariela
Brun, Lucas Ricardo Martín
García, María Laura
Sarli, Marcelo
Paula, Rey
Farias, Vanina
Zanchetta, María Belén
Giacoia, Evangelina
Salerni, Helena
Maffei, Laura
Premrou, Valeria
Oliveri, Beatriz
Brance, María Lorena
Pavlove, Magdalena
Karlsbrum, Silvia
Larroudé, María Silvia
Costanzo, Pablo René
author Guelman, Rodolfo
author_facet Guelman, Rodolfo
Sánchez, Ariel
Varsavsky, Mariela
Brun, Lucas Ricardo Martín
García, María Laura
Sarli, Marcelo
Paula, Rey
Farias, Vanina
Zanchetta, María Belén
Giacoia, Evangelina
Salerni, Helena
Maffei, Laura
Premrou, Valeria
Oliveri, Beatriz
Brance, María Lorena
Pavlove, Magdalena
Karlsbrum, Silvia
Larroudé, María Silvia
Costanzo, Pablo René
author_role author
author2 Sánchez, Ariel
Varsavsky, Mariela
Brun, Lucas Ricardo Martín
García, María Laura
Sarli, Marcelo
Paula, Rey
Farias, Vanina
Zanchetta, María Belén
Giacoia, Evangelina
Salerni, Helena
Maffei, Laura
Premrou, Valeria
Oliveri, Beatriz
Brance, María Lorena
Pavlove, Magdalena
Karlsbrum, Silvia
Larroudé, María Silvia
Costanzo, Pablo René
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Teriparatide
Bone Mineral Density
Bone Markers
Real-Life
topic Teriparatide
Bone Mineral Density
Bone Markers
Real-Life
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6-12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR.
Fil: Guelman, Rodolfo. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Sánchez, Ariel. Centro de Endocrinología; Argentina
Fil: Varsavsky, Mariela. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
Fil: Brun, Lucas Ricardo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Laboratorio de Biología Ósea; Argentina
Fil: García, María Laura. Sanatorio Julio Méndez; Argentina
Fil: Sarli, Marcelo. Universidad del Salvador; Argentina
Fil: Paula, Rey. Universidad del Salvador; Argentina
Fil: Farias, Vanina. Universidad del Salvador; Argentina
Fil: Zanchetta, María Belén. Universidad del Salvador; Argentina
Fil: Giacoia, Evangelina. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Salerni, Helena. Consultorios de Investigación Clínica Endocrinológica y del Metabolismo Óseo; Argentina
Fil: Maffei, Laura. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Premrou, Valeria. Consultorios Asociados de Endocrinología Dra. Laura Maffei; Argentina
Fil: Oliveri, Beatriz. Mautalen Salud E Investigación; Argentina
Fil: Brance, María Lorena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Reumatología y Enfermedades Óseas; Argentina
Fil: Pavlove, Magdalena. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Karlsbrum, Silvia. Gobierno de la Ciudad Autónoma de Buenos Aires. Hospital General de Agudos Carlos Durand; Argentina
Fil: Larroudé, María Silvia. Centro Rossi; Argentina
Fil: Costanzo, Pablo René. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentina
description Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-sectional study of postmenopausal women treated with TPTD for at least 12 months. Results. 264 patients were included in the study. Main characteristics are as follows: age: 68.7 ± 10.2 years, previous fractures: 57.6%, and previously treated with antiresorptive (AR-prior): 79%. All bone turnover markers studied significantly increased after 6 months. CTX and BGP remained high up to 24 months, but total and bone alkaline phosphatase returned to basal values at month 18. There was a significant increase in lumbar spine (LS) BMD after 6 months (+6.2%), with a maximum peak at 24 months (+13%). Femoral neck (FN) and total hip (TH) BMD showed a significant increase later than LS (just at month 12), reaching a maximum peak at month 24 (FN + 7.9% and TH + 5.5%). A significant increase in LS BMD was found from month 6 to month 24 compared to basal in both AR-naïve, and AR-prior patients (+16.7% and +10.5%, respectively), without significant differences between the two groups. Comparable results were found in FN and TH BMD. Main conclusions. As reported in real-life clinical studies, treatment of osteoporotic postmenopausal women with TPTD induced a significant increase in bone turnover markers from month 6 onward and an increase in BMD from months 6-12 with continuous gain up to month 24. The real-life results of our study matched the results of randomized clinical trials. In addition, TPTD induced an increase in BMD, regardless of the previous use of AR.
publishDate 2023
dc.date.none.fl_str_mv 2023-01
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/218895
Guelman, Rodolfo; Sánchez, Ariel; Varsavsky, Mariela; Brun, Lucas Ricardo Martín; García, María Laura; et al.; Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience; Hindawi Publishing Corporation; International Journal of Endocrinology; 2023; 9355672 ; 1-2023; 1-8
1687-8337
1687-8345
CONICET Digital
CONICET
url http://hdl.handle.net/11336/218895
identifier_str_mv Guelman, Rodolfo; Sánchez, Ariel; Varsavsky, Mariela; Brun, Lucas Ricardo Martín; García, María Laura; et al.; Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience; Hindawi Publishing Corporation; International Journal of Endocrinology; 2023; 9355672 ; 1-2023; 1-8
1687-8337
1687-8345
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1155/2023/9355672
info:eu-repo/semantics/altIdentifier/url/https://www.hindawi.com/journals/ije/2023/9355672/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Hindawi Publishing Corporation
publisher.none.fl_str_mv Hindawi Publishing Corporation
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613682860916736
score 13.070432

Publicaciones similares